April 09, 2020 + Jessica Di Palo
5 Minuten zu lesen
The $50 million round will support the TytoCare to continue to scale business activities globally, as well as respond to the increase in demand for their digital health solutions.
MTIP, the pan-European specialist Healthtech investor, took part in the newest financing round for Fund I Portfolio Company TytoCare. The $50 million round will support the Company to continue to scale business activities globally, as well as respond to the increase in demand for their digital health solutions.
In these troubling times caused by COVID-19, when we all face social isolation and governments impose restrictions upon us, we need to constantly monitor these impacts on our selected portfolio companies. As the demand for telehealth is accelerating, we are proud that TytoCare, the healthcare industry’s first all-in-one modular device and telehealth platform for on-demand, remote medical examinations, closed a financing round of $50 million, bringing the Company’s total capital raised to more than $105 million.
TytoCare’s product TytoHome, an easy to use toolkit that offers on-demand medical exams for patients, is a unique telehealth diagnostic solution. The Israeli digital health Company allows patients to self–monitor, and the data to be sent remotely to physicians, allowing them to oversee patients without exposure to a disease. In Switzerland the health inscurance Company SWICA will be testing TytoHome with 2000 of their customers until the end of 2020. The insurer reports that their pilot project has been very popular and that all devices have been successfully assigned.
«This round of financing will allow Tyto Care to focus even more on the needs of patients to develop new devices that build on their telehealth platform», said Dr. Christoph Kausch Managing Partner of MTIP. He adds: «Furthermore, we see the Company’s development as a confirmation of our investment thesis». MTIP recognized several years ago that the system was not able to keep up with demand, and the healthcare sector would need to innovate and leverage new technologies to continue to operate at a sustainable level. One of the key pillars of MTIP’s investment thesis is the need for decentralization. In an environment where we are all isolated in our homes, it is companies like TytoCare that are of particular necessity. MTIP is confident in the defensiveness of the Healthtech sector and our ability to continue to make successful investments throughout the cycle. It is with great pleasure that we look back on the previous relationship between TytoCare and MTIP and look forward to how this symbiosis will continue to grow in the future.
As TytoCare CEO and Co-founder Dedi Gilad noted: «MTIP has played and will continue to play a vital role in opening doors and creating potential partnerships throughout Europe. Building on the success and excitement for TytoCare in the US, we are pleased to be partnering with such a knowledgeable digital health investor whose unique position will help us further transform telehealth and reach more homes around the globe, especially in Europe.»
Christoph Kausch selected by Real Deals as most influential for 2022
Christoph Kausch named by Real Deals most influential for 2022
MTIP leads €17 million financing round in virtual fertility clinic Apricity
New MTIP investment
MTIP leads the €20 million growth financing round in LynxCare
Largest capital round ever in digital health in Belgium
Pioneering the use of machine learning algorithms to turbo-charge drug development
Intelligencia revolutionizes drug development
The psychology of decision making
What makes a good investor?
MTIP schliesst zweiten Healthtech Growth Fonds mit $250 Millionen
MTIP schliesst zweiten Healthtech Fund
Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics
Cynerio's new product Cynerio Now!
MTIP invests in Mediktor
Dieser Text erscheint auf allen Übersichtsseiten (z.B. Story-Karussell)
MTIP invests in Mediktor
MTIP investiert in medizinischen Assistenten
SFDR Art. 8 or Art. 9? What’s the difference?
SFDR: getting the terminology right
MTIP participates in Oviva’s new $80m Series C funding
MTIP invests in Oviva
MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence
MTIP's new investment in Intelligencia
Leading brands revolutionize care journeys with Lumeon
How Lumeon orchestrates care journey
Trialbee – our hero in patient matching and recruiting for clinical trials
Trialbee - patient matching and recruiting
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
How to pitch to a healthtech Investor
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health
MTIP scored fantastic grades in the UNPRI assessment report of 2020
UNPRI Report grades 2020
4 Health VCs Share Their Business Priorities and What is Next
MTIP invests in Trialbee
New investment in Trialbee
TytoCare closes $50 million round as the demand for telehealth accelerates
TytoCare closes new round